Product Description: Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016 Sep 9;5(10):e1226720./[2]Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023 Nov 8;15(11):e17804./[3]Maximilian Pinho-Schwermann, et al. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade.doi https://doi.org/10.1101/2023.11.15.567201/[4]Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691./[5]Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.
CAS Number: 1228763-95-8
Molecular Weight: N/A
Compound Purity: 99.69
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: Checkpoint Kinase (Chk);IFNAR
English
Deutsch
